Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D: Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D: Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin

Published

April 30, 2018

Created by

CMEducation Resources symposium